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regression analysis showed an interesting, but not 
statistically significant trend: better pathological responses 
were seen in patients presenting more important reduction of 
SUVmax and SUVmean (Fig. 1). 
 
 
Conclusions: These preliminary prospective data seem to 
support the hypothesis that changes of some 18FDG-PET/CT 
values, as SUVmax and SUVmean, could predict the pathological 
response in locally advanced rectal cancer after neoadjuvant 
treatments. Further analyses are needed. 
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Purpose/Objective: To report the 4-year outcomes of a 
consecutive prospective series of anal cancer patients 
treated with concurrent chemo-radiation delivered with 
intensity-modulated radiotherapy (IM-RT), employing a 
simultaneous integrated boost (SIB) approach. 
Materials and Methods: A prospective series of 54 patients 
was enrolled between 2007 and 2013. Treatment schedule 
consisted of 50.4 Gy/28 fractions (1.8 Gy daily) to the gross 
tumor volume, while the elective nodal volumes were 
prescribed 42 Gy/28 fractions (1.5 Gy/daily) for patients 
having a cT2N0 disease. Patients with cT3-T4/N0-N3 tumors 
were prescribed 54 (T3) or 59.4 (T4) Gy/30 fractions (1.8 Gy 
daily) to the gross tumor volume; gross nodal volumes were 
prescribed 50.4 Gy/30 fr (1.68 Gy daily) if sized < 3 cm or 54 
Gy/30 fr (1.8 Gy daily) if > 3 cm; elective nodal regions were 
given 45 Gy/30 fractions (1.5 Gy daily). Chemotherapy was 
administred concurrently according to the Nigro’s regimen. 
Primary endpoints was colostomy-free survival (CFS). 
Secondary end-points were local control (LC), disease-free 
survival (DFS), cancer-specific survival (CSS), overall survival 
(OS) and toxicity profile. 
Results: Median follow up was 32.6 months (range 12-84). 
The actuarial probability of being alive at 4 years without a 
colostomy (CFS) was 68.9 % (95% CI: 50.3-84.7%). Actuarial 4-
year OS, CSS, DFS and LC were 77.7% (95% CI: 60.7-88.1%), 
81.5% (95% CI: 64-91%), 65.5% (95% CI: 47.7-78.5%) and 84.6% 
(95% CI: 71.6-92%). Actuarial 4-year metastasis-free survival 
was 74.4% (95% CI: 55.5-86.2%). Maximum detected acute 
toxicities were as follows: dermatologic – G3: 13%; GI-G3: 8%; 
GU-G3: 2%; anemia-G3: 2%; neutropenia-G3:11%; G4: 2%; 
thrombocytopenia- G3:2%. Four-year G2 chronic toxicity rates 
were 2.5% (95% CI: 3.6-16.4) for GU, 14.4% (95% CI: 7.1-28) 
for GI, 3.9% (95% CI: 1-14.5%) for skin and 4.2% (95% CI: 1.1-
15.9) for genitalia.  
Conclusions: Our findings support the feasibility of IMRT in 
the combined modality treatment of anal cancer, with 
comparable results to the literature with respect to local 
control, spinchter preservation and survival. Acute toxicity is 
lower if compared to series employing standard techniques. 
Our results support the use of IMRT on a routine basis for the 
treatment of anal cancer. 
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Purpose/Objective: To analyze results of combined 
treatment of adjuvant radio-chemotherapy in patients 
diagnosed with gall-bladder cancer after complete resection. 
Materials and Methods: Since June 1993 until March 2013, 87 
patients with the diagnosis of gallbladder cancer who 
underwent extended or simple cholecystectomy and were 
staged as T1b-2-3N0-1M0, received adjuvant radio-
chemotherapy at Instituto Oncológico, Viña del Mar. Overall 
survival and median survival were analyzed in relation to 
different prognostic factors, using Kaplan-Meier techniques 
